Grade: Pharmaceutical Grade
Factory Location: Xiamen, Fujian
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East
Monthly Production Capacity: 1000kg
Packaging Information: 25kg/drum 1kg/bottle
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/L
Product name
|
Molnupiravir / EIDD-2801 / MK448
|
CAS No.
|
2349386-89-4
|
Molecular Formula
|
C13H19N3O7
|
Molecular Weight
|
329.31
|
Quality Standard
|
98% up by HPLC
|
Appearance
|
White powder
|
ITEMS
|
SPECIFICATION
|
RESULT
|
Appearance
|
White to off-white powder
|
White powder
|
Solubility
|
Sparingly soluble in methanol ,practically insoluble in water
|
Complies
|
Identity
|
IR Spectrum of the test is concordant with the IR spectrum of the standard, obtained in the samemanner.
|
Complies
|
Related
Substance
|
Any single impurity not more than 0.1%
|
0.04%
|
Total impurities are not more than1.0%
|
0.1%
|
Limit of
residual solvents
|
2-propanol ≤ 5000ppm
|
75 ppm
|
Ethanol ≤ 5000ppm
|
162 ppm
|
Ethyl acetate ≤ 5000ppm
|
Not detected
|
Cyclohexane ≤ 3880ppm
|
1 ppm
|
Loss on drying
|
≤ 0.5%
|
0.12%
|
Residue on ignition
|
≤ 0.1%
|
0.03%
|
Heavy metals
|
≤ 0.02%
|
Complies
|
Assay
|
98.0～102.0%
|
99.5%
|
Conclusion
|
Complies with the specification
|
Function of Molnupiravir
Molnupiravir / EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad-spectrum antiviral activity against influenza virus and multiple coronaviruses (e.g., SARS-ChemicalbookCoV-2, MERS-CoV, SARS-CoV). EIDD-2801 has the potential to treat the novel coronavirus COVID-19 as well as seasonal and pandemic influenza.
|
Language
